|
Nanotechnology Tenants
Dendritic Nanotechnologies
DNT is the world’s leading developer and provider of advanced
dendritic polymers, a breakthrough enabling technology that provides the vehicle
— the targeting and delivery mechanisms — for a vast array of diagnostic and
therapeutics solutions — in vitro and in vivo.
 Artificial Cell Technologies
Artificial Cell Technologies, Inc. is an early-stage biomedical
nanotechnology company founded in 2002 to commercialize applications of a
new proprietary technology platform involving designed polypeptides. Our
long term vision is to commercialize biotechnology applications for
successively more sophisticated versions of an artificial bionanomachine:
the artificial cell. ACT was founded to achieve this artificial cell
vision by commercializing biomedical applications of our proprietary
polypeptide nanostructure technology platform, starting with one of the
simplest of human cells, the red blood cell. ACT’s technology platform
includes proprietary methods for manufacturing custom-designed polypeptide
films and microcapsules with controlled, tunable biological, chemical, and
physical properties.
Nanotechnology Affiliates
Please contact the CEO at CMU-RC
if interested in becoming an affiliate member of the Dendrimer Center.
Ken Van Der Wende
President and CEO
Central Michigan University Research Corporation
E-mail:
k.vanderwende@cmich.edu Phone:
(989) 774-1574
|
|
CMURC BI FORUM: Using Analytics and
Predictive Modeling to Manage in Turbulent Times,
June 12, 8:30am to 5:00pm in Mt. Pleasant, MI
>>more
JOB POSTING: Receptionist/Office Assistant
>>more
|
